Table 1.
Baseline characteristics. The table summarizes the patients' clinicopathological data and the rs11623866 genotype distribution in the AGO-OVAR-15 subgroup genetics trial, with regard to the lonafarnib treated arm and the non-treated arm
| All | TC arm | LTC arm | ||||
|---|---|---|---|---|---|---|
| Characteristic | n | % | n | % | n | % |
| Number of patients | 57 | 100 | 27 | 47.4 | 30 | 52.6 |
| Age (years), median (range) | 56 | (21–74) | 56 | (41–74) | 59 | (21–71) |
| Performance status | ||||||
| ECOG 0 | 28 | 49.1 | 13 | 48.1 | 15 | 50.0 |
| ECOG 1 | 27 | 47.4 | 13 | 48.1 | 14 | 46.7 |
| ECOG 2 | 2 | 3.5 | 1 | 3.7 | 1 | 3.3 |
| FIGO stage | ||||||
| IIB-III | 47 | 82.5 | 23 | 85.2 | 24 | 80.0 |
| IV | 10 | 17.5 | 4 | 14.8 | 6 | 20.0 |
| Histology | ||||||
| Serous | 42 | 73.7 | 20 | 74.1 | 22 | 73.3 |
| Endometroid | 4 | 7.0 | 3 | 11.1 | 1 | 3.3 |
| Mucinous | 3 | 5.3 | 2 | 7.4 | 1 | 3.3 |
| Other | 8 | 14.0 | 2 | 7.4 | 6 | 20.0 |
| Primary tumour | ||||||
| Ovary | 52 | 91.2 | 23 | 85.2 | 29 | 96.7 |
| Fallopian tube | 0 | 0 | 0 | |||
| Peritoneum | 5 | 8.8 | 4 | 14.8 | 1 | 3.3 |
| Histologic grading | ||||||
| G1 | 2 | 3.5 | 0 | 2 | 6.7 | |
| G2 | 20 | 35.1 | 12 | 44.4 | 8 | 26.7 |
| G3 | 33 | 57.9 | 14 | 51.9 | 19 | 63.3 |
| Unknown | 2 | 3.5 | 1 | 3.7 | 1 | 3.3 |
| rs11623866 G > C | ||||||
| GG | 20 | 35.1 | 13 | 48.2 | 7 | 23.3 |
| GC | 28 | 49.1 | 10 | 37.0 | 18 | 60.0 |
| CC | 9 | 15.8 | 4 | 14.8 | 5 | 16.7 |
LTC, lonafarnib + TC;
TC, taxane (paclitaxel) + carboplatin.